Drug intelligence / Profile preview

ONC-001 (Omic)

Development stage: Preclinical
Lead developer: Omic
Administration: Intravenous

Overview

ONC-001 is a cancer immunotherapy drug candidate being developed by Omic Analytics (Omic.ai), an AI-driven drug discovery company. It is currently in the lead optimization phase of preclinical development and has been computationally validated. ONC-001 is characterized as an immune checkpoint inhibitor (ICI) designed to act on multiple undisclosed targets. While the specific molecular targets and modality (such as whether it is a small molecule or a biologic) have not been publicly disclosed, the drug is intended to modulate immune checkpoints to enhance the body's anti-tumor response.

Targets

TXNRD1 (Thioredoxin reductase 1)

Beyond the preview

Go deeper on ONC-001 (Omic).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ONC-001 (Omic).

Explore the full profile